On 22 January 2026, Zhitong Finance reported that AstraZeneca’s Imfinzi® (durvalumab) was approved by China’s National Medical Products Administration (NMPA) for use, in combination with carboplatin and paclitaxel, as a first-line treatment for adult patients with mismatch repair-deficient (dMMR) primary advanced or recurrent endometrial cancer, followed by maintenance therapy with durvalumab alone.
Imfinzi® has been approved for this indication in other jurisdictions, including the US (June 2024), the EU (August 2024) and Australia (where it is listed on the PBS as of August 2025).
To date, there have been no announcements of any therapeutic durvalumab biosimilars in development.